肥胖与头颈癌新辅助免疫治疗病理缓解的相关性:一项初步研究
该单中心回顾性队列纳入42例接受新辅助免疫检查点抑制剂(ICI)±化疗的头颈鳞癌(HNSCC)患者,肥胖定义为BMI≥30 kg/m2。多因素分析显示肥胖与病理缓解几率降低独立相关(OR 0.10,95%CI 0.02-0.72;p=0.021),BMI每增加1 kg/m2缓解几率降低15%(OR 0.85,95%CI 0.72-0.99;p=0.039)。
要点
- 肥胖HNSCC患者新辅助ICI病理缓解率低于非肥胖者(29% vs. 69%)。
- 肥胖与病理缓解几率降低独立相关(OR 0.10,95%CI 0.02-0.72;p=0.021)。
- BMI每增加1 kg/m2,病理缓解几率降低15%(OR 0.85,95%CI 0.72-0.99)。
核心结论
- 在小型初步队列中,肥胖与HNSCC新辅助ICI病理缓解降低相关。
- 该结果与复发/转移场景中的「肥胖悖论」相反,提示代谢状态与免疫治疗反应的关系可能具有情境依赖性。
研究设计与样本
- 单中心三级学术中心回顾性队列研究,纳入42例接受新辅助ICI±化疗的HNSCC患者。
- 肥胖定义为BMI≥30 kg/m2,主要结局为任何病理缓解(部分、主要或完全缓解)。
- 采用多因素logistic回归校正吸烟状态和ECOG体能状态,并将BMI作为连续变量分析。
- 证据等级为III级。
主要发现
- 7例(17%)患者为肥胖。
- 肥胖患者病理缓解率低于非肥胖患者(29% vs. 69%)。
- 多因素分析中肥胖与缓解几率降低相关(OR 0.10,95%CI 0.02-0.72;p=0.021)。
- BMI每增加1 kg/m2与缓解几率降低15%独立相关(OR 0.85,95%CI 0.72-0.99;p=0.039)。
- 校正后预测缓解概率从BMI 18时约85%降至BMI 40时25%;在仅接受免疫治疗亚组中,BMI增加仍与缓解降低相关(OR 0.66,95%CI 0.44-0.99;p=0.045)。
临床怎么用
- 对接受新辅助ICI的HNSCC患者,可将BMI作为潜在疗效预测因素纳入评估。
- 肥胖患者新辅助免疫治疗前应与患者沟通可能较低的病理缓解概率。
局限性
- 样本量小(42例),肥胖患者仅7例,为初步结果。
- 单中心回顾性设计,结论需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate associations between obesity and pathologic response to neoadjuvant immune checkpoint inhibitors (ICI) in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: This was a retrospective cohort study conducted at a single tertiary academic center. We identified 42 patients with HNSCC treated with neoadjuvant ICI with or without chemotherapy. Obesity was defined as body mass index (BMI) ≥ 30 kg/m2. The primary outcome was any pathologic response (partial, major, or complete response). Multivariable logistic regression was performed to assess associations between obesity and response, adjusting for smoking status and Eastern Cooperative Oncology Group (ECOG) performance status. BMI was also analyzed as a continuous variable. Adjusted predicted probabilities of response were estimated across BMI. RESULTS: Seven patients (17%) were obese. Obese patients had lower rates of pathologic response compared to non-obese patients (29% vs. 69%). On multivariable analysis, obesity was associated with decreased odds of response (OR 0.10, 95% CI 0.02-0.72; p = 0.021). Increasing BMI was independently associated with lower odds of response, with a 15% decrease per 1 kg/m2 increase [OR 0.85 (0.72-0.99), p = 0.039]. Adjusted predicted probability of response declined from ~85% at BMI 18 to 25% at BMI 40. In a subset of patients receiving immunotherapy alone, increasing BMI remained associated with decreased response [OR 0.66 (0.44-0.99), p = 0.045]. CONCLUSION: In a small pilot cohort, obesity was associated with decreased pathologic response to neoadjuvant ICI in HNSCC. These findings contrast with the "obesity paradox" observed in recurrent/metastatic settings and suggest the relationship between metabolic state and immunotherapy response may be context-dependent. Further validation in larger cohorts is needed. LEVEL OF EVIDENCE: III.
引用
- Truong AA, Chen L, Lee RH, et al. Obesity and Pathologic Response to Neoadjuvant Immunotherapy in Head and Neck Cancer: Preliminary Results From a Pilot Study. Head Neck. 2026. PMID: 42904484. doi:10.1002/hed.70505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。